ST
MYGN icon

Smithfield Trust’s Myriad Genetics MYGN Stock Holding History

Smithfield Trust’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-84
Closed -$2K – 1055
2024
Q1 		$2K Buy
+84
New +$1.81K ﹤0.01% 1013
2020
Q1 		– Sell
-65
Closed -$2K – 992
2019
Q4 		$2K Hold
65
– – ﹤0.01% 912
2019
Q3 		$2K Hold
65
– – ﹤0.01% 951
2019
Q2 		$2K Hold
65
– – ﹤0.01% 935
2019
Q1 		$2K Hold
65
– – ﹤0.01% 902
2018
Q4 		$2K Hold
65
– – ﹤0.01% 889
2018
Q3 		$3K Hold
65
– – ﹤0.01% 913
2018
Q2 		$2K Hold
65
– – ﹤0.01% 977
2018
Q1 		$2K Hold
65
– – ﹤0.01% 990
2017
Q4 		$2K Buy
+65
New +$2.19K ﹤0.01% 1040

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Smithfield Trust's MYGN Position: Q2 2024 in Review

Smithfield Trust sold out of Myriad Genetics (MYGN) in Q2 2024, closing a stake of 84 shares — an estimated $2K sold.

Smithfield Trust first reported a position in MYGN in Q4 2017 and held it in 10 quarters. The position peaked at $3K in Q3 2018. 223 funds tracked by Wall St. Rank hold MYGN as of Q2 2024.

  • Smithfield Trust reported no remaining Myriad Genetics position as of Q2 2024 after selling out during the quarter.
  • Smithfield Trust sold 84 Myriad Genetics shares in Q2 2024, an estimated $2K.
  • Smithfield Trust first reported a position in Myriad Genetics in Q4 2017 and held it in 10 quarters.
  • Smithfield Trust's Myriad Genetics position peaked at $3K in Q3 2018.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2024.

Based on Smithfield Trust's 13F filing for Q2 2024, filed 31 Jul 2024.